On May 15–16, 2026, the 25th China Biological Products Congress (CBioPC2026) concluded successfully at Nanjing International Expo Center. The event gathered more than 6,000 domestic and foreign experts, scholars and industry representatives. Centering on cutting-edge fields such as vaccines, recombinant therapeutic products, cell and gene therapy, it built an authoritative exchange platform for in-depth integration of industry, academia, research and application.

HZSKBIO^Ⓡ showcased its three core platforms including HCP detection, pyrogen detection and rapid microbial detection at the exhibition. It also delivered an academic report at the recombinant therapeutic products sub-forum, boosting the quality control upgrading of biological products with solid technological strength and innovative solutions.

At CBioPC2026, Dou Minhua, Senior R&D Director of HZSKBIO^Ⓡ, delivered a special report titled Discussion on Host Cell Protein (HCP) Analysis Strategy and Its Impact on Endotoxin Detection. Focusing on the core pain points of process impurity control for biotech drugs, she shared cutting-edge technological achievements and practical experience, attracting extensive attention from the industry. In accordance with the latest regulatory requirements of USP, EP and Chinese Pharmacopoeia, the report systematically sorted out the current research status of HCP and key points of ELISA method development, and focused on analyzing the interference mechanism of residual HCP on endotoxin detection.

At the exhibition site, HZSKBIO^Ⓡ fully presented its one-stop quality control solutions for biological products. Its core technologies and products were highly recognized by on-site experts and enterprise representatives:

• HCP Residual Detection Platform: It covers multiple expression systems including CHO, Escherichia coli and yeast, and provides general/process-specific ELISA kits, antibody coverage verification and high-risk HCP testing services to meet demands from IND stage to commercialization.

• Pyrogen Detection Platform: Targeting complex matrix interference, it launched recombinant cascade reagents, anti-interference pretreatment kits and MAT method, solving difficulties such as inhibitory interference and low recovery rate, and complying with pharmacopoeia requirements.

• Rapid Microbial Detection Platform: It covers rapid testing solutions for bacteria/fungi, mycoplasma, mycobacteria, adventitious viruses and more, balancing sensitivity, specificity and efficiency to facilitate rapid risk control.

The on-site technical team had in-depth exchanges with participants, and provided customized solutions for impurity removal, method verification, release testing and other demands of antibody drugs, recombinant proteins and cell therapy products, fully demonstrating the company’s technical accumulation and service capacity in the field of pharmaceutical quality control.

The remarkable appearance at CBioPC 2026 not only highlights HZSKBIO^Ⓡ’s leading advantages in HCP analysis, microbial detection, pyrogen detection and other fields, but also strengthens in-depth connections with industry peers. Going forward, HZSKBIO^Ⓡ will continue to take innovative technologies and compliant solutions as the core, offer full-process support for the R&D, production and supervision of biological products, and help China’s biomedical industry advance toward higher quality, greater safety and higher efficiency.